(Q51564055)

7 April 2018

title

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. (English)

1 reference

7 April 2018

polycystic ovary syndrome

main subject

1 reference

1 reference

1 reference

Glueck CJ

1

1 reference

7 April 2018

Wang P

2

1 reference

7 April 2018

Fontaine R

3

1 reference

7 April 2018

Tracy T

4

1 reference

7 April 2018

Sieve-Smith L

5

1 reference

7 April 2018

publication date

1 April 1999

1 reference

7 April 2018

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

7 April 2018

volume

48

1 reference

7 April 2018

issue

4

1 reference

7 April 2018

page(s)

511-519

1 reference

7 April 2018

Insulin-sensitising agents in polycystic-ovary syndrome.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Clinical assessment of body hair growth in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Polycystic ovary syndrome: a changing perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Insulin sensitizing agents and polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Lack of linear relationship between hyperinsulinaemia and hyperandrogenism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990113-0

10.1016/S0026-0495(99)90113-0

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10206447

1 reference

7 April 2018